![]() |
|
|
Vol. 300, Issue 1, 34-42, January 2002
9-Tetrahydrocannabinol and Other Cannnabinoids
Department of Pharmacology, Kirksville College of Osteopathic
Medicine, Kirksville, Missouri
Cannabinoids, including the endogenous cannabinoid or endocannabinoid,
anandamide, modulate several gastrointestinal functions. To date, the
gastrointestinal effects of the second putative endocannabinoid 2-arachidonoylglycerol (2-AG) have not been studied. In the present study using a shrew (Cryptotis parva) emetic model, 2-AG
(0.25-10 mg/kg, i.p.) potently and dose-dependently increased vomiting frequency (ED50 = 1.13 mg/kg) and the number of
animals vomiting (ED50 = 0.48 mg/kg). In contrast,
neither anandamide (2.5-20 mg/kg) nor methanandamide (5-10 mg/kg)
induced a dose-dependent emetogenic response, but both could partially
block the induced emetic effects.
9-Tetrahydrocannabinol
and its synthetic analogs reduced 2-AG-induced vomiting with the rank
order potency: CP 55,940 > WIN 55,212-2 >
9-tetrahydrocannabinol. The nonpsychoactive cannabinoid,
cannabidiol, was inactive. Nonemetic doses of SR 141716A (1-5 mg/kg)
also blocked 2-AG-induced vomiting. The 2-AG metabolite arachidonic
acid also caused vomiting. Indomethacin, a cyclooxygenase inhibitor,
blocked the emetogenic effects of both arachidonic acid and 2-AG. CP
55,940 also blocked the emetic effects of arachidonic acid. 2-AG
(0.25-10 mg/kg) reduced spontaneous locomotor activity
(ED50 = 11 mg/kg) and rearing frequency
(ED50 = 4.3 mg/kg) in the shrew, whereas such doses of
both anandamide and methanandamide had no effect on locomotor
parameters. The present study indicates that: 1) 2-AG is an efficacious
endogenous emetogenic cannabinoid involved in vomiting circuits, 2) the
emetic action of 2-AG and the antiemetic effects of tested cannabinoids
are mediated via CB1 receptors, and 3) the emetic effects
of 2-AG occur in lower doses relative to its locomotor suppressant actions.
This article has been cited by other articles:
![]() |
J. Guo and S. R. Ikeda Endocannabinoids Modulate N-Type Calcium Channels and G-Protein-Coupled Inwardly Rectifying Potassium Channels via CB1 Cannabinoid Receptors Heterologously Expressed in Mammalian Neurons Mol. Pharmacol., March 1, 2004; 65(3): 665 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Iversen Cannabis and the brain Brain, June 1, 2003; 126(6): 1252 - 1270. [Abstract] [Full Text] [PDF] |
||||